COMP <GO>
ABT vs JNJ // OPERATING MARGIN
Abbott Laboratories (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ABT 4
— JNJ 10
▲ OPERATING MARGIN LEADER: JNJ
LAST: $106.20 (+1.56%) • MKT CAP: $180.95B
operating-margins
18.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
operating-margins
34.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.40% | 67.90% | -11.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 25.50% | -13.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 18.5x | -0.10 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 2.97% | +1.12 | ABT | /fcf-yield <GO> |
| Operating Margin ACTIVE | 18.20% | 34.70% | -16.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 28.50% | -13.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 6.00% | -0.30 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 0.00% | +2.27 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.36 | 5.59 | -1.23 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | ABT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.5 | 60.4 | -0.83 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.08 | -0.09 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 23.0x | +2.80 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $180.95B | $662.49B | -$481.55B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | JNJ REV | ABT GROSS % | JNJ GROSS % | ABT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $94.19B | 56.4% | 67.9% | $7.39B | $19.70B |
| FY 2024 | $41.95B | $88.82B | 55.4% | 69.1% | $6.35B | $19.84B |
| FY 2023 | $40.11B | $85.16B | 44.0% | 44.0% | $5.46B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
JNJ // BETA 1.08